as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,712.0
Change
-4.0 (-0.23%)
Open
₹1,716.0
Prev. Close
₹1,716.0
Day High
₹1,727.9
Day Low
₹1,699.5
Volume Analysis
Traded
624,705
Delivered
288,914
Delivery %
46.25%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Trading within 3% of its 52-week high (₹1740.0)
- •Strong operating margin (20.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year EPS growth (22.4%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,755.16 | ₹1,741.53 | ₹1,726.76 | ₹1,713.13 | ₹1,698.36 | ₹1,684.73 | ₹1,669.96 |
| Fibonacci | ₹1,741.53 | ₹1,730.68 | ₹1,723.98 | ₹1,713.13 | ₹1,702.28 | ₹1,695.58 | ₹1,684.73 |
| Camarilla | ₹1,719.81 | ₹1,717.21 | ₹1,714.6 | ₹1,713.13 | ₹1,709.4 | ₹1,706.79 | ₹1,704.19 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+43.5%
1 Week
-0.08%
1 Month
+4.05%
3 Months
+8.44%
6 Months
+27.56%
1 Year
+57.06%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹940.84
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
9.49%
Net margin 10.62% × asset turnover 0.58x × equity multiplier 1.54x
Company Overview
Sector
Healthcare
Market Cap
₹98,939 Cr
P/E (TTM)
26.2
ROE
10.1%
Book Value
₹652.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Aurobindo Pharma Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Growth (46/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹1740.0); strong operating margin (20.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
70/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 2.64 times its book value
- −The company has delivered a poor sales growth of 6.32% over past five years.
- −Company has a low return on equity of 10.8% over last 3 years.
- −Company might be capitalizing the interest cost
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Trading window closes from October 1, 2026 until 48 hours after Q2 and half-year results.
Aurobindo Pharma will attend JP Morgan Healthcare Trip group meeting in Hyderabad on September 24, 2026.
US FDA inspection at Apitoria’s Unit-II, Telangana, ended with one procedural observation on September 15, 2026.
USFDA final approval received for Beclomethasone Dipropionate HFA inhalation aerosol; first MDI product, launch upcoming quarters.
A1 Biochem Labs India subscribed 10,000 shares of A1 Biochem USA Inc for USD 1 million on September 11, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 6,851 | 7,219 | 7,352 | 7,580 | 7,567 | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 |
| Expenses + | 5,702 | 5,846 | 5,753 | 5,920 | 5,949 | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,873 | 7,103 | 7,271 |
| Operating Profit | 1,149 | 1,373 | 1,599 | 1,660 | 1,618 | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 | 1,773 | 1,750 | 1,880 |
| OPM % | 17.0% | 19.0% | 22.0% | 22.0% | 21.0% | 20.0% | 20.0% | 21.0% | 20.0% | 20.0% | 21.0% | 20.0% | 21.0% |
| Other Income + | 47 | 188 | 163 | 14 | 221 | 136 | 159 | 135 | 107 | 122 | 123 | 117 | 224 |
| Interest | 57 | 68 | 76 | 89 | 111 | 113 | 118 | 115 | 98 | 95 | 93 | 98 | 102 |
| Depreciation | 327 | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 | 465 | 479 | 487 |
| Profit before tax | 812 | 1,076 | 1,262 | 1,230 | 1,324 | 1,207 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 | 1,291 | 1,515 |
| Tax % | 30.0% | 30.0% | 26.0% | 26.0% | 31.0% | 32.0% | 30.0% | 32.0% | 32.0% | 34.0% | 32.0% | 29.0% | 32.0% |
| Net Profit + | 570 | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 |
| EPS in Rs | 10 | 13 | 16 | 16 | 16 | 14 | 15 | 16 | 14 | 15 | 16 | 16 | 18 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 12,103 | 13,772 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 | 34,935 |
| Expenses + | 9,524 | 10,579 | 11,469 | 12,691 | 15,612 | 18,249 | 19,497 | 19,060 | 21,148 | 23,176 | 25,164 | 26,783 | 27,854 |
| Operating Profit | 2,579 | 3,193 | 3,441 | 3,772 | 3,952 | 4,849 | 5,278 | 4,396 | 3,707 | 5,826 | 6,560 | 6,870 | 7,081 |
| OPM % | 21.0% | 23.0% | 23.0% | 23.0% | 20.0% | 21.0% | 21.0% | 19.0% | 15.0% | 20.0% | 21.0% | 20.0% | 20.0% |
| Other Income + | 81 | 200 | 115 | 105 | 70 | 166 | 3,195 | 152 | 291 | 366 | 613 | 404 | 586 |
| Interest | 160 | 257 | 67 | 78 | 263 | 305 | 74 | 49 | 140 | 290 | 457 | 384 | 388 |
| Depreciation | 333 | 392 | 428 | 558 | 668 | 967 | 1,055 | 1,127 | 1,245 | 1,522 | 1,649 | 1,778 | 1,859 |
| Profit before tax | 2,168 | 2,744 | 3,061 | 3,241 | 3,091 | 3,743 | 7,344 | 3,373 | 2,612 | 4,380 | 5,066 | 5,112 | 5,420 |
| Tax % | 28.0% | 26.0% | 25.0% | 25.0% | 24.0% | 24.0% | 27.0% | 22.0% | 26.0% | 28.0% | 31.0% | 31.0% | — |
| Net Profit + | 1,571 | 2,024 | 2,301 | 2,423 | 2,364 | 2,844 | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | 3,503 | 3,711 |
| EPS in Rs | 27 | 35 | 39 | 41 | 40 | 49 | 91 | 45 | 33 | 54 | 60 | 60 | 64 |
| Dividend Payout % | 8.0% | 7.0% | 6.0% | 6.0% | 6.0% | 6.0% | 4.0% | 20.0% | 23.0% | 8.0% | 0.0% | 7.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 | 32,595 | 37,833 |
| Borrowings + | 4,451 | 5,041 | 3,364 | 4,770 | 6,967 | 5,826 | 5,339 | 2,851 | 5,286 | 6,648 | 8,263 | 8,073 |
| Other Liabilities + | 3,303 | 3,568 | 3,464 | 4,492 | 5,414 | 6,113 | 6,147 | 6,211 | 7,379 | 8,227 | 8,566 | 12,232 |
| Total Liabilities | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 58,196 |
| Fixed Assets + | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,396 | 9,374 | 10,532 | 11,024 | 14,493 | 14,794 | 17,407 |
| CWIP | 420 | 848 | 1,458 | 1,583 | 1,668 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 | 4,900 | 5,214 |
| Investments | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 | 252 | 1,051 |
| Other Assets + | 8,765 | 10,745 | 9,662 | 12,527 | 15,768 | 16,827 | 20,390 | 18,362 | 22,549 | 25,983 | 29,536 | 34,525 |
| Total Assets | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 58,196 |
| Equity Capital | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 | 58 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,016 | 2,387 | 2,435 | 3,925 | 5,526 |
| Cash from Investing Activity + | -1,017 | -1,446 | -1,787 | -1,927 | -2,904 | -1,563 | 597 | -3,211 | -3,971 | -4,242 | -1,866 | -2,630 |
| Cash from Financing Activity + | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | 1,814 | 800 | 120 | -1,269 |
| Net Cash Flow | 313 | 340 | -424 | 892 | 666 | 871 | 2,561 | -1,164 | 230 | -1,007 | 2,178 | 1,628 |
| CFO/OP | 67 | 67 | 118 | 70 | 61 | 106 | 87 | 143 | 84 | 72 | 86 | 107 |
| Free Cash Flow | 491 | -146 | 1,594 | 714 | 114 | 2,969 | 1,503 | 2,693 | -323 | -1,067 | 1,408 | 2,468 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 7.43% | 6.85% | 6.87% | 6.69% | 6.45% | 6.67% | 6.61% | 6.88% | 6.37% | 6.55% | 7.08% | 6.63% |
| Promoters | 51.84% | 51.84% | 51.84% | 51.8% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.88% |
| Government | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.03% | 0.05% | 0.05% |
| FII | 22.45% | 20.72% | 18.01% | 16.73% | 16.59% | 16.29% | 15.33% | 14.38% | 14.21% | 13.95% | 15.24% | 16.38% |
| DII | 18.29% | 20.6% | 23.28% | 24.77% | 25.14% | 25.21% | 26.23% | 26.93% | 27.6% | 27.66% | 25.82% | 25.05% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Aurobindo Pharma Ltd (this stock) | 98,939 | 26.2 | 2.64 | 10.1% |
| Max Healthcare Ins Ltd | 98,694 | 65.9 | 9.22 | 14.7% |
| Manipal Health Enterpri L | 98,193 | 111.0 | — | 12.7% |
| Dr. Reddy S Laboratories | 101,096 | 31.4 | 2.67 | 11.2% |
| Lupin Limited | 95,788 | 16.1 | 4.26 | 28.7% |
| Mankind Pharma Limited | 102,225 | 47.9 | 6.27 | 13.1% |
| Laurus Labs Limited | 108,438 | 99.2 | 20.44 | 18.3% |
Which Mutual Funds Hold Aurobindo Pharma Ltd?
Frequently Asked Questions about Aurobindo Pharma Ltd
Aurobindo Pharma Ltd (AUROPHARMA) closed at ₹1,712.0 on NSE on 25 September 2026, down 4.0 (0.23%) from the previous close.
Aurobindo Pharma Ltd trades on the NSE (National Stock Exchange of India) under the symbol AUROPHARMA.
Aurobindo Pharma Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 26.2.
Aurobindo Pharma Ltd has a dividend yield of 0.23%.
Aurobindo Pharma Ltd's 52-week high is ₹1,740.0 and its 52-week low is ₹1,066.0.
Aurobindo Pharma Ltd has a market capitalisation of ₹98,939 crore.
Aurobindo Pharma Ltd has a TopFund Quality Score of 70/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Aurobindo Pharma Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.